Metastatic Breast Cancer
Conditions
Keywords
Patients who participated in UMCC 9900/9901 (Phase II Studies of Tailored-Dose Docetaxel in Metastatic Breast Cancer)
Brief summary
The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if this is in any way associated with how the patient responded to docetaxel. They also want to examine the genes in the tumor that are responsible for the production of CYP metabolizing enzymes, to see if they are normal or if they have polymorphisms, or change compared to 'normal' CYP metabolizing enzymes.
Interventions
None listed
Sponsors
University of Michigan Rogel Cancer Center
Study design
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who participated on UMCC 9900/9901 * Living patients must give written informed consent
Exclusion criteria
* No tumor block tissue available
Countries
United States
Outcome results
None listed